Goserelin as ovarian protection in the adjuvant treatment of premenopausal breast cancer: a phase II pilot study
Authors:
- Francesco RecchiaFRFrancesco Recchia
- Gigliola SicaGSGigliola Sica
- Sandro De FilippisSFSandro De Filippis
- Gaetano SaggioGSGaetano Saggio
- Michele RosselliMRMichele Rosselli
- Silvio ReaSRSilvio Rea
- 1 April 2002
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Anti-Cancer Drugs
- Vol. 13 (4) , 417-424
Abstract
The aim of the present trial was to investigate the protective effects on ovarian function, and the efficacy and tolerability of goserelin added to adjuvant chemotherapy for early breast cancer. Following surgical treatment, 64 premenopausal patients with early breast cancer received goserelin 3.6 mg (every 28 days for 1 year) and an adjuvant treatment which was chosen according to the patient's prognosis. Median age was 42 years (range 27–50). ECOG performance status was 0–1 in all patients. Twenty-eight patients (44%) had estrogen receptor (ER)+ tumors and 36 (56%) patients had ER– tumors. Fifty-two (81%) patients had stage II disease and 12 (19%) had stage III disease. Eighteen patients received cyclophosphamide, methotrexate and 5-fluorouracil chemotherapy, 46 patients received an anthracycline-based regimen, and nine of them received high-dose chemotherapy and autologous peripheral blood progenitor cell transplantation. Fifty-one patients (80%) were irradiated. ER+ patients also received tamoxifen for 5 years. Serum estradiol was suppressed to values below 40 pg/ml in all patients. After a median follow-up of 55 months, 86% of patients had resumed normal menses, 84% of patients were disease-free and 94% were alive. The 1-, 3- and 5-year projected recurrence-free survival rates were 100, 81 and 75%, respectively. Five years after treatment one patient had a pregnancy that ended with a normal childbirth. No unexpected adverse events were reported. These data show that the addition of goserelin to adjuvant therapy of premenopausal patients with early breast cancer is well tolerated and protects long-term ovarian function.Keywords
This publication has 24 references indexed in Scilit:
- Polychemotherapy for early breast cancer: an overview of the randomised trialsThe Lancet, 1998
- Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: results of the international Breast Cancer Study Group (IBCSG) trial VIEuropean Journal of Cancer, 1998
- Postoperative Radiotherapy in High-Risk Premenopausal Women with Breast Cancer Who Receive Adjuvant ChemotherapyNew England Journal of Medicine, 1997
- Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer.Journal of Clinical Oncology, 1996
- Combined effects of estradiol, leuprorelin, tamoxifen and medroxyprogesterone acetate on cell growth and steroid hormone receptors in breast cancer cellsJournal of Cancer Research and Clinical Oncology, 1994
- Protective effects of D-Trp6-luteinising hormone-releasing hormone microcapsules against cyclophosphamide-induced gonadotoxicity in female ratsBritish Journal of Cancer, 1990
- Gonadotropin releasing hormone (GnRH) analogs for the treatment of breast and prostatic carcinomaBreast Cancer Research and Treatment, 1986
- Growth of human breast cancer cells inhibited by a luteinizing hormone-releasing hormone agonistNature, 1985
- Ovarian irradiation and prednisone following surgery and radiotherapy for carcinoma of the breastBreast Cancer Research and Treatment, 1983
- Reporting results of cancer treatmentCancer, 1981